Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport.

Moritaka GotoShinji FurutaSatoko YamashitaHiroyuki HashimotoWataru YanoNoriyuki InoueNoriaki KatoKohei Kaku

Published in: Journal of diabetes investigation (2018)

These findings suggest that anagliptin might exert a cholesterol-lowering action through DPP-4-dependent and glucagon-like peptide 1-independent suppression of intestinal cholesterol transport.

Keyphrases

low density lipoprotein
type diabetes
cardiovascular events
high fat diet induced
metabolic syndrome
adipose tissue